Sanofi
Why Robinhood?
You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!About SNY
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories.
SNY Key Statistics
Stock Snapshot
The current Sanofi(SNY) stock price is $48.14, with a market capitalization of 118.67B. The stock trades at a price-to-earnings (P/E) ratio of 11.80 and offers a dividend yield of 3.4%.
On 2025-12-17, Sanofi(SNY) stock moved within a range of $47.30 to $48.41. With shares now at $48.14, the stock is trading +1.8% above its intraday low and -0.6% below the session's peak.
Trading activity shows a volume of 3.09M, compared to an average daily volume of 3.05M.
Over the past 52 weeks, Sanofi(SNY) stock has traded between a high of $60.12 and a low of $44.62.
Over the past 52 weeks, Sanofi(SNY) stock has traded between a high of $60.12 and a low of $44.62.
SNY News
Cytokinetics (CYTK), Incorporated announced that MYQORZO has been approved by the China National Medical Products Administration, NMPA, for the treatment of adu...
(RTTNews) - Sanofi (SNY, SNYNF, SAN.PA) announced that the European Medicines Agency (EMA) has granted orphan designation to efdoralprin alfa (SAR447537), forme...
Dren Bio, a privately held, clinical-stage biotechnology company, has a new collaboration with Sanofi SA (NASDAQ:SNY) . The new agreement is built on the existi...
More SNY News
Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...
On Monday, Sanofi SA (NASDAQ:SNY) announced results from the PERSEUS phase 3 study of tolebrutinib compared to placebo for primary progressive multiple sclerosi...
...
Sanofi (SNY) said it anticipates that the review process for the ongoing U.S. regulatory review of tolebrutinib in non-relapsing secondary progressive multiple...
Sanofi (SNY) announced that results from the PERSEUS phase 3 study showed that tolebrutinib did not meet its primary endpoint in delaying time to 6-month compos...
Sanofi, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain from Bank of America Securities maintained a Buy rating...
Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the yea...
